ODAC Votes in Favor of Remestemcel-L for GvHD
(WorldNews Japan)

U.S. FDA ADVISORY COMMITTEE VOTES NINE TO ONE IN FAVOR OF REMESTEMCEL-L (RYONCIL™) FOR EFFICACY IN CHILDREN WITH STEROID- REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE Melbourne, Australia; August 14, 2020; and New York, USA; August 13, 2020: Mesoblast Limited (ASX:MSB; Nasdaq: MESO), global leader in cellular medicines for inflammatory diseases, today announced that the Oncologic Drugs Advisory Committee (ODAC) of the United States Food and Drug Administration (FDA) voted overwhelmingly in favor that the available data support the efficacy of remestemcel-L (RYONCIL™) in pediatric patients with steroid-refractory acute graft versus host disease (SR-aGVHD). Mesoblast Chief Medical Officer Dr...